{"filing":{"accession_number":"0001326190-26-000056","cik":"0001326190","ticker":"ALT","company_name":"Altimmune, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-24","primary_document":"alt-20260924x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000056/alt-20260924x8k.htm"},"events":[{"id":35581,"run_id":32780,"accession_number":"0001326190-26-000056","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Board appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026. This is a clear executive appointment to a named officer role with significant accounting and financial reporting responsibilities. The disclosure includes detailed background on his 28 years of finance and accounting experience and prior roles at major companies, consistent with standard executive appointment disclosures under Item 5.02.","company_name":"Altimmune, Inc.","ticker":"ALT","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39676,"accession_number":"0001326190-26-000056","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026. This is a clear executive appointment to a named officer role with significant accounting and financial reporting responsibilities. The disclosure includes detailed background on his 28 years of finance and accounting experience and prior roles at major companies, consistent with standard executive appointment disclosures under Item 5.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:04:45.603538+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39676,"accession_number":"0001326190-26-000056","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026. This is a clear executive appointment to a named officer role with significant accounting and financial reporting responsibilities. The disclosure includes detailed background on his 28 years of finance and accounting experience and prior roles at major companies, consistent with standard executive appointment disclosures under Item 5.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:04:45.603538+00:00","company_name":"Altimmune, Inc.","ticker":"ALT","filing_date":"2026-09-29"}]}